Rick Yang Buys 207,100 Shares of Korro Bio (NASDAQ:KRRO) Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Rick Yang purchased 207,100 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The stock was acquired at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the completion of the purchase, the insider directly owned 1,297,893 shares of the company’s stock, valued at $14,419,591.23. This represents a 18.99% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Korro Bio Stock Down 2.2%

Shares of NASDAQ:KRRO traded down $0.26 during midday trading on Thursday, hitting $11.50. The stock had a trading volume of 92,041 shares, compared to its average volume of 184,676. The company’s 50-day moving average price is $10.90 and its 200-day moving average price is $20.23. The company has a market capitalization of $108.33 million, a P/E ratio of -1.22 and a beta of 2.98. Korro Bio, Inc. has a fifty-two week low of $5.20 and a fifty-two week high of $55.89.

Korro Bio (NASDAQ:KRRO) last announced its earnings results on Thursday, March 12th. The company reported ($5.32) EPS for the quarter. The company had revenue of $1.29 million during the quarter. Korro Bio had a negative net margin of 1,199.53% and a negative return on equity of 68.87%. Research analysts expect that Korro Bio, Inc. will post -9.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Korro Bio

Institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. purchased a new stake in Korro Bio during the third quarter worth approximately $39,000. Wells Fargo & Company MN increased its stake in Korro Bio by 45.5% during the fourth quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock valued at $60,000 after purchasing an additional 2,352 shares during the last quarter. Guggenheim Capital LLC acquired a new position in Korro Bio during the 4th quarter valued at approximately $84,000. Jain Global LLC acquired a new position in Korro Bio during the 4th quarter valued at about $85,000. Finally, Deutsche Bank AG grew its stake in shares of Korro Bio by 241.9% in the fourth quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock worth $102,000 after purchasing an additional 9,027 shares in the last quarter. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Multiple major shareholders and investors materially bought stock on March 10 — including Anthony A. Florence Jr., Paul E. Walker, Mohamad Makhzoumi, Edward T. Mathers, Forest Baskett, Rick Yang, Scott D. Sandell and Enterprise Associates 17 New — each acquiring 207,100 shares at $11.11, increasing their individual stakes by ~18.99%. Insider and large‑holder purchases often signal confidence in company prospects. SEC Filing (example)
• Positive Sentiment: Company reported an oversubscribed $85 million private placement that management says extends the cash runway into H2 2028 — reduces near‑term financing risk and supports ongoing programs. The corporate update also cited nominations of development candidates (KRRO‑121 for hyperammonemia indications and an advanced GalNAc conjugate program for alpha‑1 antitrypsin deficiency), indicating R&D progress. GlobeNewswire Press Release
• Negative Sentiment: Quarterly results were weak: KRRO reported a Q4 EPS loss of $(5.32), far worse than the consensus loss of $(1.93), with only $1.29M in revenue and a deeply negative net margin and ROE. The magnitude of the miss raises execution and cost concerns and likely pressured the stock despite the financing and insider buying. Zacks Coverage of Q4 Results

Wall Street Analyst Weigh In

A number of analysts have recently commented on KRRO shares. JonesTrading cut Korro Bio from a “buy” rating to a “hold” rating in a research report on Friday, November 14th. Clear Str raised shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 18th. Wall Street Zen cut shares of Korro Bio from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Cantor Fitzgerald downgraded Korro Bio from an “overweight” rating to a “neutral” rating in a research report on Thursday, November 13th. Finally, Royal Bank Of Canada downgraded shares of Korro Bio from an “outperform” rating to a “sector perform” rating in a report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $50.38.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.